F. Arguc
6 Papers
F. Arguc is an academic researcher. The author has contributed to research in topics: Innate immune system & Proinflammatory cytokine. The author has co-authored 2 publications.
Chat about Author
Papers
Engineering pancreatic islets with a novel form of thrombomodulin protein to overcome early graft loss triggered by instant blood-mediated inflammatory reaction.
Ali Turan,Lei Zhang,Mohammad Tarique,Vahap Ulker,F. Arguc,Darshan Badal,Esma S. Yolcu,Haval Shirwan +7 more
TL;DR: In this paper , a chimeric form of thrombomodulin with streptavidin (SA-TM) was used for transient display on the surface of islets modified with biotin to mitigate the instant blood-mediated inflammatory reaction (IBMIR), which causes substantial islet loss after intraportal transplantation.
4
Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth
Martín R. Ramos-González,Mohammad Tarique,Lalita Batra,F. Arguc,Rodolfo Garza-Morales,Haval Shirwan,Esma S. Yolcu,Jorge G. Gomez-Gutierrez +7 more
TL;DR: Oncolytic adenovirus armed with a novel agonist of the CD137 immune checkpoint stimulator suppresses tumor growth by inducing T-cell proliferation and activating programmed cell death.
1
Abstract 3286: Development and characterization of an oncolytic adenovirus armed with the immune checkpoint stimulator SA-4-1BBL
Jorge G. Gomez-Gutierrez,Martin Ramos-Gonzalez,Rodolfo Garza-Morales,Mohammad Tarique,F. Arguc,Lalita Batra,Haval Shirwan,Esma S. Yolcu +7 more
TL;DR: The data suggests that OAd expressing the immune checkpoint stimulator SA-4-1BBL may represent alternative therapeutic strategy against lung cancer, which could be used alone or in combination with immune checkpoint inhibitors, or other approaches aimed at enhancing the anti-tumor immune response.
Abstract 2465: A novel agonist of CD137 as a single agent shows cancer immunoprevention efficacy against various tumor types that is not dependent on the trained immunity
F. Arguc,Mohammad Tarique,Vahap Ulker,Esma S. Yolcu,Haval Shirwan +4 more
TL;DR: SA-4-1BBL exhibits cancer immunoprevention efficacy against various tumor types as a single agent, which is not dependent on trained immunity.
Progesterone signaling in oviductal epithelial cells modulates the immune response to support preimplantation embryonic development
Emily A. McGlade,Kalli K Stephens,Ryan M. Marquardt,F. Arguc,Peter F. Lais,San-Pin Wu,Sarayut Winuthayanon,Haval Shirwan,Esma S. Yolcu,Mark I. Hunter,James K. Pru,John P. Lydon,F. J. DeMayo,Wipawee Winuthayanon +13 more